VIALE, GIUSEPPE
VIALE, GIUSEPPE
Dipartimento di Oncologia ed Emato-Oncologia
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy
2025 K. Venetis, G. Cursano, R. Scafetta, P.P.M.B. Giachetti, A. Concardi, E. De Camilli, M. D'Ercole, E. Mane, C. Frascarelli, A. Marra, S. Gandini, F. Pepe, S. Scagnoli, S.M. Rossi, R. Troiano, E. Speziale, C. De Angelis, G. Troncone, U. Malapelle, G. Perrone, A. Botticelli, G. Viale, G. Curigliano, E. Guerini Rocco, C. Criscitiello, N. Fusco
Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ
2024 E. Guerini-Rocco, F. Bellerba, A. Concardi, S.V. Taormina, G. Cammarata, C. Fumagalli, A. Guerrieri-Gonzaga, D. Macis, E. Del Fiol Manna, E. Balladore, M. Cannone, P. Veronesi, N. Fusco, B. Bonanni, G. Viale, M. Barberis, S. Gandini, M. Lazzeroni
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research
2024 F. Conforti, L. Pala, T. De Pas, E. Zattarin, C. Catania, E. Cocorocchio, G. Rossi, D. Laszlo, M. Colleoni, A. Zambelli, G.N. Hortobagyi, J. Cortes, M.J. Piccart, M. Dowsett, R.D. Gelber, G. Viale
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer
2024 M. Ivanova, F.M. Porta, M. D'Ercole, C. Pescia, E. Sajjadi, G. Cursano, E. De Camilli, O. Pala, G. Mazzarol, K. Venetis, E. Guerini-Rocco, G. Curigliano, G. Viale, N. Fusco
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis
2024 L. Pala, E. Pagan, I. Sala, C. Oriecuia, M. Oliari, T. De Pas, C. Specchia, E. Cocorocchio, E. Zattarin, G. Rossi, C. Catania, G.L. Ceresoli, D. Laszlo, J. Canzian, E. Valenzi, G. Viale, R.D. Gelber, A. Mantovani, V. Bagnardi, F. Conforti
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial
2023 D. Serrano, S. Gandini, P. Thomas, K.D. Crew, N.B. Kumar, L.A. Vornik, J.J. Lee, P. Veronesi, G. Viale, A. Guerrieri-Gonzaga, M. Lazzeroni, H. Johansson, M. D'Amico, F. Guasone, S. Spinaci, B. Bertelsen, G. Mellgren, I. Bedrosian, D. Weber, T. Castile, E. Dimond, B.M. Heckman-Stoddard, E. Szabo, P.H. Brown, A. Decensi, B. Bonanni
Immune microenvironment dynamics in breast cancer during pregnancy: impact of gestational age on tumor-infiltrating lymphocytes and prognosis
2023 E. Sajjadi, K. Venetis, M. Ivanova, M. Noale, C. Blundo, E. Di Loreto, G. Scarfone, S. Ferrero, S. Maggi, P. Veronesi, V.E. Galimberti, G. Viale, F.A. Peccatori, N. Fusco, E. Guerini-Rocco
The molecular landscape of breast mucoepidermoid carcinoma
2023 K. Venetis, E. Sajjadi, M. Ivanova, S. Andaloro, S. Pessina, C. Zanetti, A. Ranghiero, G. Citelli, C. Rossi, M. Lucioni, U. Malapelle, F. Pagni, M. Barberis, E. Guerini-Rocco, G. Viale, N. Fusco
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread
2023 C. Criscitiello, C. Corti, M. De Laurentiis, G. Bianchini, B. Pistilli, S. Cinieri, L. Castellan, G. Arpino, P. Conte, F. DI MECO, A. Gennari, V. Guarneri, L. Visani, L. Livi, P. Marchetti, F. Puglisi, G. Viale, L. Del Mastro, S. De Placido, G. Curigliano
Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies
2023 C. Pescia, E. Guerini-Rocco, G. Viale, N. Fusco
TMEM123 a key player in immune surveillance of colorectal cancer
2023 E. Pesce, C. Cordiglieri, M. Bombaci, S. Eppenberger-Castori, S. Oliveto, C. Manara, M. Crosti, C. Ercan, M. Coto, A. Gobbini, S. Campagnoli, T. Donnarumma, M. Martinelli, V. Bevilacqua, E. De Camilli, P. Gruarin, M.L. Sarnicola, E. Cassinotti, L. Baldari, G. Viale, S. Biffo, S. Abrignani, L.M. Terracciano, R. Grifantini
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
2023 L. Ferrando, A. Vingiani, A. Garuti, C. Vernieri, A. Belfiore, L. Agnelli, G. Dagrada, D. Ivanoiu, G. Bonizzi, E. Munzone, L. Lippolis, M. Dameri, F. Ravera, M. Colleoni, G. Viale, L. Magnani, A. Ballestrero, G. Zoppoli, G. Pruneri
CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one- carbon metabolism in breast cancer
2022 M.G. Filippone, D. Gaglio, R. Bonfanti, F.A. Tucci, E. Ceccacci, R. Pennisi, M. Bonanomi, G. Jodice, M. Tillhon, F. Montani, G. Bertalot, S. Freddi, M. Vecchi, A. Taglialatela, M. Romanenghi, F. Romeo, N. Bianco, E. Munzone, F. Sanguedolce, G. Vago, G. Viale, P.P. Di Fiore, S. Minucci, L. Alberghina, M. Colleoni, P. Veronesi, D. Tosoni, S. Pece
Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis
2022 N. Bianco, M. Milano, E. Pagan, C. Oriecuia, V. Bagnardi, E.G. Rocco, G.I. Santomauro, G. Peruzzotti, M. Colleoni, G. Viale
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy
2022 S. Pece, I. Sestak, F. Montani, M. Tillhon, P. Maisonneuve, S. Freddi, K. Chu, M. Colleoni, P. Veronesi, D. Disalvatore, G. Viale, R. Buus, J. Cuzick, M. Dowsett, P.P. Di Fiore
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study
2022 B. Acs, S.C.Y. Leung, K.M. Kidwell, I. Arun, R. Augulis, S.S. Badve, Y. Bai, A.L. Bane, J.M.S. Bartlett, J. Bayani, G. Bigras, A. Blank, H. Buikema, M.C. Chang, R.L. Dietz, A. Dodson, S. Fineberg, C.M. Focke, D. Gao, A.M. Gown, C. Gutierrez, J. Hartman, Z. Kos, A.-. Laenkholm, A. Laurinavicius, R.M. Levenson, R. Mahboubi-Ardakani, M.G. Mastropasqua, S. Nofech-Mozes, C.K. Osborne, F.M. Penault-Llorca, T. Piper, M.A. Quintayo, T.T. Rau, S. Reinhard, S. Robertson, R. Salgado, T. Sugie, B. van der Vegt, G. Viale, L.A. Zabaglo, D.F. Hayes, M. Dowsett, T.O. Nielsen, D.L. Rimm
Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement
2022 E. Guerini-Rocco, G. Botti, M.P. Foschini, C. Marchio, M.G. Mastropasqua, G. Perrone, E. Roz, A. Santinelli, I. Sassi, V. Galimberti, L. Gianni, G. Viale
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
2022 K. Venetis, E. Crimini, E. Sajjadi, C. Corti, E. Guerini-Rocco, G. Viale, G. Curigliano, C. Criscitiello, N. Fusco
Sex and cancer immunotherapy: Current understanding and challenges
2022 L. Pala, T. De Pas, C. Catania, G. Giaccone, A. Mantovani, S. Minucci, G. Viale, R.D. Gelber, F. Conforti
Breast Cancer during Pregnancy as a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles
2022 E. Sajjadi, K. Venetis, M. Noale, H.A. Azim, C. Blundo, G. Bonizzi, E. Di Loreto, G. Scarfone, S. Ferrero, S. Maggi, M. Barberis, P. Veronesi, V.E. Galimberti, G. Viale, N. Fusco, F.A. Peccatori, E. Guerini-Rocco